Adial Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/21/23
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement and Reduce the Public FloatGlobeNewsWire • 08/04/23
Adial Provides Business Update Following Favorable Comments from US and EU Regulatory MeetingsGlobeNewsWire • 07/11/23
Adial Pharmaceuticals to Present at the 2023 Jefferies Global Healthcare Conference on June 9thGlobeNewsWire • 06/01/23
Adial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/12/23
Adial Pharmaceuticals Receives Notice of Exercise from Adovate for the Acquisition of Purnovate's Assets and BusinessGlobeNewsWire • 05/10/23
Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 04/04/23
Adial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business UpdateGlobeNewsWire • 03/30/23
Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use DisorderGlobeNewsWire • 03/21/23
Adial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14thGlobeNewsWire • 03/08/23
Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use DisorderGlobeNewsWire • 03/06/23
Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct OfferingGlobeNewsWire • 02/27/23
Adial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct OfferingGlobeNewsWire • 02/24/23
Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to AdenomedGlobeNewsWire • 02/01/23
Adial Pharmaceuticals, Inc. (ADIL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 12/01/22
Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 11/14/22
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate's PNV-5030 as a Potential Treatment for Chronic PainGlobeNewsWire • 09/26/22
Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate's PNV-6005 as a Potential Treatment for Ulcerative ColitisGlobeNewsWire • 09/06/22
Here's Why Adial Pharmaceuticals, Inc. (ADIL) Could be Great Choice for a Bottom FisherZacks Investment Research • 09/01/22